[Traditional Chinese and Western medicine in the treatment of 27 patients with malignant lymphoma].
Twenty-seven patients with malignant lymphoma (14 Hodgkin's disease, 9 histiocytosarcoma, 2 plasmacytoma, 2 lympholeucosarcoma) were treated by Ailin-injection plus Chinese herbal medicine. The latter's composition and dose varied depending on the clinical manifestations. All the patients had stage III and IV lesions. The total remission rate was 70.37% (complete remission 13 patients, partial remission 6 patients, no remission 8 patients). In addition, we also studied the suppressive effect of Ailin on transplanted tumor in vivo (S-180). The suppression rates were 36.09%, 48.80%, 32.67% by three repetitions with an average of 39.18% (P less than 0.002). They were 37.25%, 35.29% on S37 with an average of 36.27% (P less than 0.005). They were 46.53%, 44.56%, 51.35%, 45.95% on Ehrlich ascites tumor cells with an average of 47.09% (P less than 0.001). The clinical and experimental studies suggest that Ailin-1 has no serious side effects and is well tolerated by patients with malignant lymphoma at moderate or advanced stages. No toxic reactions were observed at the clinical dose. In the above combination therapy, the Chinese herbal medicine has obvious supplementary effect in the treatment of the patients' cachexia and immuno-suppression.
Haerbin University of Medical Sciences.
Y S
YS
Li
T D
TD
Zhang
C W
CW
Li
X L
XL
Zhao
Z R
ZR
Wei
W
W
Tan
R L
RL
Li
Y Y
YY
Ma
D000293:Adolescent; D000328:Adult; D000818:Animals; D001152:Arsenicals / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004339:Drug Compounding; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008628:Mercury / Q000627:therapeutic use; D051379:Mice; D008875:Middle Aged; D012510:Sarcoma 180 / Q000188:drug therapy; D012511:Sarcoma 37 / Q000188:drug therapy
D001152:Arsenicals; D004365:Drugs, Chinese Herbal; D008628:Mercury